• Earlier in May 2026, Rigel Pharmaceuticals announced an exclusive global licensing agreement with Arvinas and Pfizer for VEPPANU (vepdegestrant), an FDA‑approved oral PROTAC for certain advanced or metastatic ER+/HER2-, ESR1‑mutated breast cancers.
• This deal makes VEPPANU Rigel’s fourth commercial product and the first approved PROTAC in its portfolio, potentially reshaping the company’s oncology focus and product mix.
• We’ll now examine how adding VEPPANU as a globally licensed, FDA‑approved breast cancer therapy could influence Rigel’s existing investment narrative.

The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Rigel Pharmaceuticals Investment Narrative Recap

To own Rigel today, you need to believe it can turn a small, concentrated portfolio into a broader, sustainable oncology business without losing profitability. VEPPANU adds an FDA approved breast cancer drug and a first PROTAC to that story, but it does not remove the near term risk that revenue is still concentrated in a few products and that earnings include sizeable noncash items.

The most relevant recent announcement alongside VEPPANU is Rigel’s reaffirmed 2026 guidance for total revenue of about US$275 million to US$290 million and positive net income. That outlook was issued before the VEPPANU license and already assumes profitable operations, so investors may watch closely how management integrates this new asset while still hitting those near term financial targets.

Yet even with VEPPANU, investors should be aware that Rigel’s heavy dependence on a handful of products and one time revenue benefits...

Rigel Pharmaceuticals' narrative projects $297.0 million revenue and $42.4 million earnings by 2028. This implies 3.5% yearly revenue growth but a decrease of $55.4 million in earnings from $97.8 million today.

Uncover how Rigel Pharmaceuticals' forecasts yield a $51.60 fair value, a 78% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts paint a far tougher picture, expecting earnings to drop to about US$47.3 million by 2029, so if you are weighing VEPPANU’s impact you should know their view hinges on shrinking margins and slower growth that could be very different if Rigel executes well on its new breast cancer franchise.

Explore 6 other fair value estimates on Rigel Pharmaceuticals - why the stock might be worth over 3x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Rigel Pharmaceuticals research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Rigel Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Rigel Pharmaceuticals' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 42 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.